Vilaprisan

Drug Profile

Vilaprisan

Alternative Names: BAY 1002670; S-PRAnt; S-PRM; sPRM

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 23 May 2017 Bayer initiates enrolment in the phase III ASTEROID 6 trial for Uterine leiomyoma in Finland (PO) (EudraCT2016-004822-41)
  • 18 May 2017 Phase-III clinical trials in Uterine leiomyoma in Austria (PO) (EudraCT2016-002855-48)
  • 18 May 2017 Phase-III clinical trials in Uterine leiomyoma (PO) in Finland (EudraCT2016-002855-48) (Bayer pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top